We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baidu, Inc. (BIDU - Free Report) recently announced a public offering of notes aggregating $1.5 billion. These notes have been issued in two tranches of different amounts, with varying coupon rates and maturities.
The first tranche of $1 billion carries an interest rate of 3.875% and is due in 2023 while the second tranche of $500 million, which has an interest rate of 4.375%, is due in 2028.
The company stated that the transaction proceeds will be used to repay existing debt and for general corporate purposes.
Notably, the stock has outperformed the industry it belongs to on a 12-month basis. The company’s shares have gained 39.7% compared with the industry’s growth of 11.1%.
Baidu’s Cash Position
At the end of fourth-quarter 2017, cash, cash equivalents and short-term investments were RMB100.5 billion ($15.44 billion). Net operating cash inflow was RMB 10.0 billion ($1.53 billion) and capital expenditures were RMB 1.2 billion ($183 million).
We believe that the company has a strong balance sheet, which will help it to capitalize on investment opportunities, further improving its growth prospects. The senior notes’ offering will bring down the company’s cost of capital, in our view, thus strengthening its balance sheet and supporting growth.
Bottom Line
Baidu provides Internet search services in China. It also offers a Chinese language search platform for businesses to reach their customers.
Baidu’s increasing presence in the autonomous driving space is helping inimprovingits competitive position. Just recently, the company got the long-awaited go-ahead to conduct open-road tests for its autonomous driving vehicles in designated areas in Beijing. This makes Baidu the first company to receive licenses for conducting road tests in Beijing, which is a big positive.
Some of the current buoyancy surrounding the shares is related to the company’s dominance in the mobile search market andonline video as well asits consistent product development efforts. We believe that it has significant growth potential in the mobile market over the long term.
However, higher promotional expenses, heavy spending on new growth areas and increasing competition in its own search platform poseas concerns.
Long-term earnings per share growth rate for Teradyne, PetMed and Brady Corporation is projected to be 14%, 10% and 7.5%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Baidu (BIDU) Announces Notes Offering Worth $1.5 Billion
Baidu, Inc. (BIDU - Free Report) recently announced a public offering of notes aggregating $1.5 billion. These notes have been issued in two tranches of different amounts, with varying coupon rates and maturities.
The first tranche of $1 billion carries an interest rate of 3.875% and is due in 2023 while the second tranche of $500 million, which has an interest rate of 4.375%, is due in 2028.
The company stated that the transaction proceeds will be used to repay existing debt and for general corporate purposes.
Notably, the stock has outperformed the industry it belongs to on a 12-month basis. The company’s shares have gained 39.7% compared with the industry’s growth of 11.1%.
Baidu’s Cash Position
At the end of fourth-quarter 2017, cash, cash equivalents and short-term investments were RMB100.5 billion ($15.44 billion). Net operating cash inflow was RMB 10.0 billion ($1.53 billion) and capital expenditures were RMB 1.2 billion ($183 million).
We believe that the company has a strong balance sheet, which will help it to capitalize on investment opportunities, further improving its growth prospects. The senior notes’ offering will bring down the company’s cost of capital, in our view, thus strengthening its balance sheet and supporting growth.
Bottom Line
Baidu provides Internet search services in China. It also offers a Chinese language search platform for businesses to reach their customers.
Baidu’s increasing presence in the autonomous driving space is helping inimprovingits competitive position. Just recently, the company got the long-awaited go-ahead to conduct open-road tests for its autonomous driving vehicles in designated areas in Beijing. This makes Baidu the first company to receive licenses for conducting road tests in Beijing, which is a big positive.
Some of the current buoyancy surrounding the shares is related to the company’s dominance in the mobile search market andonline video as well asits consistent product development efforts. We believe that it has significant growth potential in the mobile market over the long term.
However, higher promotional expenses, heavy spending on new growth areas and increasing competition in its own search platform poseas concerns.
Baidu, Inc. Price and Consensus
Baidu, Inc. Price and Consensus | Baidu, Inc. Quote
Zacks Rank & Stocks to Consider
Baidu carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the technology sector are Teradyne (TER - Free Report) , PetMed Express (PETS - Free Report) and Brady Corporation (BRC - Free Report) . While Teradyne sports a Zacks Rank #1 (Strong Buy), Brady Corporation and PetMed carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings per share growth rate for Teradyne, PetMed and Brady Corporation is projected to be 14%, 10% and 7.5%, respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>